Patents by Inventor Pedro Cabrales

Pedro Cabrales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11660286
    Abstract: The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: May 30, 2023
    Assignee: EPICENTRX, INC.
    Inventors: Bryan T. Oronsky, Jan Scicinski, Susan Knox, William Fitch, Frans A. Kuypers, Marcel Fens, Sandra Larkin, Pedro Cabrales, Chad Brouse
  • Publication number: 20200022952
    Abstract: The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.
    Type: Application
    Filed: February 25, 2019
    Publication date: January 23, 2020
    Inventors: Bryan T. Oronsky, Jan Scicinski, Susan Knox, William Fitch, Frans A. Kuypers, Marcel Fens, Sandra Larkin, Pedro Cabrales, Chad Brouse
  • Publication number: 20180256509
    Abstract: The present invention relates to methods for treating systemic inflammation. In certain embodiments, the method comprises administering a therapeutically effective amount of curcumin-selenium loaded nanoparticles. The curcumin-selenium loaded nanoparticles can comprise a matrix of chitosan, polyethylene glycol and tetramethoxysilane encapsulating curcumin and selenium. In certain embodiments, the method comprises administering a therapeutically effective amount of nitric oxide-releasing nanoparticles. The nitric oxide-releasing nanoparticles can comprise a matrix of chitosan encapsulating nitric oxide. In certain embodiments, the systemic inflammation can be caused by endotoxemia. In certain embodiments, the systemic inflammation can be caused by a Filovirus, including an Ebola virus or a Marburg virus. In certain embodiments, the methods for treating systemic inflammation in a subject result in the reduction of proinflammatory cytokines in a subject.
    Type: Application
    Filed: November 3, 2015
    Publication date: September 13, 2018
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., UNIVERSITY OF CALIFORNIA SAN DIEGO
    Inventors: Joel M. Friedman, Mahantesh Navati, Adam J. Friedman, Pedro Cabrales
  • Patent number: 9737478
    Abstract: The invention contemplates compositions for the treatment of malaria comprising an anti-malaria drug and an adjuvant which promotes vasodilation and methods of using same.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: August 22, 2017
    Assignee: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR)
    Inventors: Leonardo Jose de Moura Carvalho, Pedro Cabrales
  • Publication number: 20150147396
    Abstract: Nanoparticles are provided that comprise S-nitrosothiol (SNO) groups covalently bonded to the nanoparticles and/or S-nitrosothiol containing molecules encapsulated within the nanoparticles, as well as methods of making and using the nanoparticles. The invention also provides methods of preparing nanoparticles comprising Snitrosothiol (SNO) groups covalently bonded to the nanoparticles, where the methods comprise a) providing a buffer solution comprising chitosan, polyethylene glycol, nitrite, glucose, and hydrolyzed 3-mercaptopropyltrimethoxysilane (MPTS); b) adding hydrolyzed tetramethoxysilane (TMOS) to the buffer solution to produce a sol-gel; and c) lyophilizing and ball milling the sol-gel to produce nanoparticles of a desired size.
    Type: Application
    Filed: May 1, 2013
    Publication date: May 28, 2015
    Inventors: Parimala Nacharaju, Chaim Tuckman-Vernon, Adam J. Friedman, Pedro Cabrales, Joel M. Friedman
  • Publication number: 20150010644
    Abstract: Techniques are disclosed that interfere with breakdown of the mucosal barrier in the stomach and the intestine under conditions of hypoxia by administrating a therapeutic dose of an oxygen rich solution. Such solution may include one or more of perflurocarbon, ATP solution or buffer solution.
    Type: Application
    Filed: December 14, 2012
    Publication date: January 8, 2015
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Geert W. Schmid-Schonbein, Marisol Chang, Pedro Cabrales
  • Publication number: 20140308260
    Abstract: The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.
    Type: Application
    Filed: October 5, 2012
    Publication date: October 16, 2014
    Inventors: Bryan T. Oronsky, Jan Scicinski, Susan Knox, William Fitch, Frans A. Kuypers, Marcel Fens, Sandra Larkin, Pedro Cabrales, Chad Brouse
  • Publication number: 20130310325
    Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.
    Type: Application
    Filed: September 23, 2011
    Publication date: November 21, 2013
    Inventors: Geert W. Schmid-Schonbein, Yung-Tsai Lee, Jeng Wei, Marisol Chang, Pedro Cabrales
  • Publication number: 20120046231
    Abstract: Described herein is a composition and process for synthesizing a human serum albumin (HSA) based plasma replacement composition that includes a polymerized HSA (PolyHSA) that is chemically stabilized by the reduction of Schiff bases. The PolyHSA may have a molecular weight of at least about 100 kDa and may optionally have a cross-linker to HSA molar ratio of at least about 10:1. The PolyHSA composition is useful for restoring a subject's circulatory volume.
    Type: Application
    Filed: August 23, 2011
    Publication date: February 23, 2012
    Inventors: Andre Francis Palmer, Pedro Cabrales
  • Patent number: 8071546
    Abstract: The present invention is directed to uses of PEGylated albumins which include methods of treating reduced functional capillary density, reduced blood volume, septic shock and cardiac arrhythmia in a subject, which comprise administering to the subject a therapeutically effective amount of a PEGylated albumin.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: December 6, 2011
    Assignees: La Jolla Bioengineering Institute, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Pedro Cabrales, Amy Tsai, Seetharama A. Acharya, Belur N. Manjula
  • Publication number: 20110250134
    Abstract: The invention provides methods for delivering a NO molecule or precursor thereof to a vascular compartment of a subject comprising: administering to the subject, a NO particle formulation, via an intravascular, intraperitoneal, or intramuscular administration, in an amount sufficient to induce vascular smooth muscle relaxation thereby delivering the NO molecule or precursor thereof to the vascular compartment of the subject, wherein the NO particle formulation comprises NO attached to a nanoparticle or microparticle.
    Type: Application
    Filed: April 13, 2011
    Publication date: October 13, 2011
    Inventors: Pedro Cabrales, Adam Friedman, Joel M. Friedman
  • Publication number: 20110077258
    Abstract: The invention contemplates compositions for the treatment of malaria comprising an anti-malaria drug and an adjuvant which promotes vasodilation and methods of using same.
    Type: Application
    Filed: September 13, 2010
    Publication date: March 31, 2011
    Inventors: Leonardo Jose de Moura Carvalho, Pedro Cabrales
  • Publication number: 20100222260
    Abstract: The present invention is directed to uses of PEGylated albumins which include methods of treating reduced functional capillary density, reduced blood volume, septic shock and cardiac arrhythmia in a subject, which comprise administering to the subject a therapeutically effective amount of a PEGylated albumin.
    Type: Application
    Filed: June 9, 2006
    Publication date: September 2, 2010
    Inventors: Pedro Cabrales, Amy Tsai, Seetharama A. Acharya, Belur N. Manjula